Hidefumi Hiramatsu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8682555/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680
2	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1504-1506.	30.7	393
3	Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood, 2003, 102, 873-880.	1.4	253
4	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2022, 3, 66-81.	5.0	70
5	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	10.7	65
6	Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. International Journal of Hematology, 2018, 108, 66-75.	1.6	39
7	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 2021, 5, 593-601.	5.2	28
8	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2022, 36, 1508-1515.	7.2	21
9	Successful reducedâ€intensity stem cell transplantation for <scp>GATA</scp> 2 deficiency before progression of advanced <scp>MDS</scp> . Pediatric Transplantation, 2016, 20, 333-336.	1.0	20
10	Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A singleâ€institute experience. Pediatric Transplantation, 2018, 22, e13113.	1.0	19
11	Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. Journal of Clinical Oncology, 2018, 36, 900-907.	1.6	18
12	Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II–III Randomized Trial (JPLSG AML-12). Japanese Journal of Clinical Oncology, 2018, 48, 587-593.	1.3	18
13	Impact of pretransplant minimal residual disease on the postâ€ŧransplant outcome of pediatric acute lymphoblastic leukemia. Pediatric Transplantation, 2016, 20, 692-696.	1.0	12
14	Paraneoplastic hypereosinophilic syndrome associated with <i>IL3â€lgH</i> positive acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27449.	1.5	12
15	High incidence of <scp>BK</scp> virusâ€associated hemorrhagic cystitis in children after second or third allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation, 2018, 22, e13183.	1.0	11
16	Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond–Blackfan anemia. Bone Marrow Transplantation, 2021, 56, 1013-1020.	2.4	10
17	Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO) Journal of Clinical Oncology, 2020, 38, 10518-10518.	1.6	10
18	Diagnostic accuracy of endoscopic features of pediatric acute gastrointestinal graftâ€versusâ€host disease. Digestive Endoscopy, 2016, 28, 548-555.	2.3	9

HIDEFUMI HIRAMATSU

#	Article	IF	CITATIONS
19	Central nervous system recurrence of desmoplastic small round cell tumor following aggressive multimodal therapy: A case report. Oncology Letters, 2016, 11, 856-860.	1.8	8
20	Highâ€dose chemotherapy with autologous stem cell transplantation spares reâ€irradiation for recurrent intracranial germinoma. Pediatric Blood and Cancer, 2018, 65, e27104.	1.5	8
21	Successful granulocyte apheresis using medium molecular weight hydroxyethyl starch. International Journal of Hematology, 2019, 110, 729-735.	1.6	8
22	Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model. Molecular Therapy - Oncolytics, 2020, 18, 37-46.	4.4	8
23	Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. International Journal of Hematology, 2020, 111, 303-310.	1.6	7
24	Continuous deep sedation at the end of life in children with cancer: experience at a single center in Japan. Pediatric Hematology and Oncology, 2020, 37, 365-374.	0.8	6
25	Sudden spinal hemorrhage in a pediatric case with total body irradiationâ€induced cavernous hemangioma. Pediatric Blood and Cancer, 2018, 65, e27250.	1.5	5
26	Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia, 2021, 35, 2508-2516.	7.2	5
27	CD146 is a potential immunotarget for neuroblastoma. Cancer Science, 2021, 112, 4617-4626.	3.9	5
28	Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group. International Journal of Hematology, 2022, 116, 131-138.	1.6	5
29	The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlinâ€Frankfurtâ€Münster (BFM)95â€based protocol. British Journal of Haematology, 2022, 196, 1257-1261.	2.5	5
30	Whole brain radiotherapy with volumetricâ€modulated arc therapy for pediatric intracranial embryonic carcinoma prevents permanent alopecia. Pediatric Blood and Cancer, 2017, 64, e26434.	1.5	4
31	Pluripotent stem cell model of Shwachman–Diamond syndrome reveals apoptotic predisposition of hemoangiogenic progenitors. Scientific Reports, 2020, 10, 14859.	3.3	4
32	<i>PAX5</i> alterations in an infant case of <i>KMT2A</i> â€rearranged leukemia with lineage switch. Cancer Science, 2022, 113, 2472-2476.	3.9	4
33	Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma. Blood Advances, 2022, 6, 4216-4223.	5.2	4
34	Salvage therapy for children with relapsed or refractory Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26423.	1.5	3
35	Impact of postâ€ŧransplant minimal residual disease on the clinical outcome of pediatric acute leukemia. Pediatric Transplantation, 2017, 21, e12926.	1.0	3
36	Effects of cryotherapy on highâ€dose melphalanâ€induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28495.	1.5	3

HIDEFUMI HIRAMATSU

#	Article	IF	CITATIONS
37	Suppression of malignant rhabdoid tumors through Chbâ€M′â€mediated RUNX1 inhibition. Pediatric Blood and Cancer, 2021, 68, e28789.	1.5	3
38	Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia. Cancer Science, 2021, , .	3.9	3
39	A Pediatric Case of Metastatic Conventional Parosteal Osteosarcoma Treated With Multidrug Chemotherapy. Pediatric Blood and Cancer, 2016, 63, 1471-1473.	1.5	2
40	Chronic myeloid leukemia following treatment for bilateral retinoblastoma. Pediatric Blood and Cancer, 2018, 65, e27107.	1.5	2
41	Inotuzumabozogamicin is an effective treatment for CD22â€positive acute undifferentiated leukemia: A case report. Pediatric Blood and Cancer, 2021, 68, e28976.	1.5	2
42	Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL) Journal of Clinical Oncology, 2017, 35, 10523-10523.	1.6	2
43	Cytomegalovirus infection in pediatric patients with hepatoblastoma after liver transplantation. Pediatric Transplantation, 2018, 22, e13273.	1.0	1
44	RUNX inhibitor suppresses graftâ€versusâ€host disease through targeting RUNXâ€NFATC2 axis. EJHaem, 2021, 2, 449-458.	1.0	1
45	Successful reâ€administration of allâ€≺i>trans retinoic acid after acute pancreatitis. Pediatrics International, 2021, 63, 986-987.	0.5	1
46	Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2019, 134, 3848-3848.	1.4	1
47	Reduced Production of Mature Neutrophils From Induced Pluripotent Stem Cells Derived From a Severe Congenital Neutropenia Patient with HAX1 Gene Deficiency. Blood, 2011, 118, 2402-2402.	1.4	1
48	Enriched MicroRNA-126 Bioactivity Marks the Primitive Compartment In AML and Regulates LSC Numbers. Blood, 2010, 116, 94-94.	1.4	1
49	Immature teratoma of the ovary associated with Cowden syndrome. Pediatric Blood and Cancer, 2022, 69, e29555.	1.5	1
50	Chimeric antigen receptor Tâ€cell therapy for a patient with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia and leukoencephalopathy who relapsed after bone marrow transplantation. Pediatric Blood and Cancer, 2022, 69, e29734.	1.5	1
51	Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. British Journal of Haematology, 2021, 192, e7-e11.	2.5	0
52	Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19â€negative acute lymphoblastic leukemia after CARâ€T cell therapy. Pediatric Blood and Cancer, 2021, 68, e28980.	1.5	0
53	Successful right hepatic trisectionectomy following percutaneous transhepatic portal embolization in a pediatric patient with undifferentiated embryonal sarcoma of the liver. Pediatric Blood and Cancer, 2022, 69, e29369.	1.5	0
54	Reconstitution of NK Cell Receptor Repertoire after Pediatric Stem Cell Transplantation Blood, 2004, 104, 5186-5186.	1.4	0

#	Article	IF	CITATIONS
55	Generation of Human Regulatory T Cells Using NOD/SCID/γ CNULL Mice Model Blood, 2004, 104, 2787-2787.	1.4	0
56	Use of the NOD/SCID/Ĵ³cnull Mouse Model To Assess the Hepatocyte-Producing Ability of Human Hematopoietic Cells Blood, 2005, 106, 1695-1695.	1.4	0
57	Therapeutic Targeting of RUNX-NFATC2 Axis for Acute Promyelocytic Leukemia and T Cell Immunity. Blood, 2019, 134, 3359-3359.	1.4	0